Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
Healthcare
$27.96 +0.47%
+$0.16 today
- Market cap
- $2.20B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
52W Low $19.52High $35.79
Volume 0.75M
Average 0.94M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$210.94M
FY 2025 · Annual
Investing Cash Flow
$209.07M
FY 2025 · Annual
Financing Cash Flow
$2.39M
FY 2025 · Annual
-99.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.76M) |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| Deferred Income Tax | (227K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.95M | 0 | 23.89M | 34.24M | 36.22M |
| Change in Working Capital | (1.05M) | (3.9M) | 13.46M | (21.6M) | 14.06M |
| Accounts Receivables | 1.57M | (175K) | (2.28M) | 1.93M | (1.32M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.65M | 3.12M | 9.38M | 11.63M | 11.03M |
| Other Working Capital | (6.28M) | (6.85M) | 6.36M | (35.16M) | 4.34M |
| Other Non-Cash Items | (1.14M) | 9.6M | (6.22M) | (15.73M) | (5.84M) |
| Operating Cash Flow | (60.91M) | (103.73M) | (107.29M) | (157.78M) | (210.95M) |
| Capital Expenditures | (1.25M) | (1.83M) | (1.82M) | (1.92M) | (2.71M) |
| Acquisitions (Net) | 27K | 69K | 0 | 0 | 0 |
| Purchases of Investments | (389.88M) | (188.97M) | (424.56M) | (789.92M) | (384.5M) |
| Sales of Investments | 174.95M | 280.67M | 320.6M | 501.71M | 596.29M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (216.16M) | 89.94M | (105.78M) | (290.13M) | 209.07M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 269.89M | 4.08M | 216.22M | 432.3M | 2.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.48M | 0 | 2.24M | 9.15M | 0 |
| Financing Cash Flow | 272.37M | 4.08M | 218.46M | 441.45M | 2.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.69M) | (9.71M) | 5.39M | (6.46M) | 515K |
| Free Cash Flow | (62.16M) | (105.56M) | (109.11M) | (159.7M) | (213.66M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$258.8M
+ D&A$3.4M
+ Stock-Based Comp$36.2M
+ Deferred Tax$0
+ Working Capital$14.1M
- Other Non-Cash-$5.8M
= Operating Cash Flow-$210.9M
- Capex-$2.7M
= Free Cash Flow-$213.7M
Analysis
FY2025 free cash flow is -$213.7M. FCF conversion is 82.6% of net income. Operating cash flow was -$210.9M, with capex of -$2.7M. The largest bridge item is Stock-Based Comp at $36.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 8-K | Current report | Sep 22, 2026 |
Does CLDX generate free cash flow?
Celldex Therapeutics, Inc. (CLDX) generated -$213.66M of free cash flow in fiscal 2025.
How much operating cash flow does CLDX produce?
Operating cash flow was -$210.94M, before capital expenditures of $2.71M.
Continue the stock analysis
Jump to another research area for this company.